Blueprint Medicines — Investor Presentation (August 2017)
25 slides from Blueprint Medicines's investor presentation, Aug 9, 2017
Slide 1: A Blueprint for a Healthier Tomorrow
Wednesday, August 9, 2017 A Blueprint for a Healthier Tomorrow
Slide 2: Forward-looking statements
Forward-looking statements 2 This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project
Slide 3: A new way of looking at kinase medicines
A new way of looking at kinase medicines Kinome illustration reproduced courtesy of CSTI (cellsignal.com). The foregoing website is maintained by CSTI, and Blueprint Medicines is not responsible for its content. 3 BLU-554 Nexavar Sutent BLU-285 We design and develop highly targeted kinase medicines
Slide 4: A blueprint for a healthier tomorrow
A blueprint for a healthier tomorrow 4 Genomically defined cancers Rare diseases Cancer immunotherapy Oncogenic kinases resulting from tumor genetic alterations Gastrointestinal stromal tumors Hepatocellular carcinoma RET-altered cancers, including non-small cell lung cancer and medullary thyroid ca
Slide 5: Robust pipeline of diverse clinical and preclinical stage assets
Robust pipeline of diverse clinical and preclinical stage assets 5 Drug candidate Discovery Preclinical Clinical Commercial rights BLU-285 Inhibitor of KIT, including exon 17 mutations, and PDGFRα, including the D842V mutation BLU-554 Inhibitor of FGFR4 BLU-667 Inhibitor of RET fusions, mutations an
Slide 6: Key progress achieved year to date
Key progress achieved year to date Initiated Phase 1 trial of BLU-667 in RET-driven cancers 6 Completed an April 2017 offering and received ~$215M in net proceeds Received Breakthrough Therapy Designation for BLU-285 for the treatment of unresectable or metastatic PDGFRα D842V-driven GIST Establishe
Slide 7: BLU-285 Advanced GIST and Advanced Systemic Mastocytosis
BLU-285 Advanced Gastrointestinal Stromal Tumors (GIST) Advanced Systemic Mastocytosis (SM)
Slide 8: Mutant receptor tyrosine kinases are key drivers of disease in GIST
Mutant receptor tyrosine kinases are key drivers of disease in GIST 8 KIT PDGFR Extracellular Juxtamembrane Kinase-1 Kinase-2 (activation loop) Transmembrane Exons 12 18 9 11 17/18 13 Domains Primary Resistance Mutational hotspots Frequency1,2 Mutation Primary Acquired Resistance PDGFRα D842V ~5–6%
Slide 9: Beyond imatinib, there are no highly effective treatments
Beyond imatinib, there are no highly effective treatments *Represents estimated incidence for GIST patients in major markets (US, EU5 and Japan). **Represents estimated incidence for all GIST patients with PDGFRα D842V mutation in major markets (US, EU5 and Japan). 9 PDGFRα D842V GIST 1L imatinib PF
Slide 10: Tumor regression across all dose levels in PDGFR D842-mutant GIST
Tumor regression across all dose levels in PDGFR D842-mutant GIST (central radiographic review) Data previously presented in June 2017 at the ASCO Annual Meeting. Data cutoff: April 28, 2017. *Per archival tumor and ctDNA. 10
Slide 11: High response rate and prolonged PFS in PDGFR D842-mutant GIST
High response rate and prolonged PFS in PDGFR D842-mutant GIST DCR, disease control rate; mPFS, median progression free survival; ORR, objective response rate; PD, progressive disease; PFS, progression free survival; SD, stable disease. Data previously presented in June 2017 at the ASCO Annual Meet
Slide 12: Dose-dependent tumor reduction across multiple KIT genotypes
Dose-dependent tumor reduction across multiple KIT genotypes (central radiographic review) 12 *ctDNA results pending. **Per archival tumor and ctDNA. Mutational status by exon**
Slide 13: Important clinical activity in heavily pre-treated KIT-mutant GIST
Important clinical activity in heavily pre-treated KIT-mutant GIST Data previously presented in June 2017 at the ASCO Annual Meeting. Data cutoff: April 28, 2017. **Kang et al. Lancet Oncol. 2013; 14(12): 1175-82 13 Central radiographic review *1 confirmed, 1 pending confirmation ↑ PFS with BLU-285
Slide 14: Safety results showed BLU-285 was well tolerated
Safety results showed BLU-285 was well tolerated Most adverse events were Grade 1 or 2 Across all grades, the most common adverse events included nausea (60%), fatigue (53%), vomiting (42%), periorbital edema (36%), diarrhea (33%), and peripheral edema (31%) Investigators reported treatment-related
Slide 15: BLU-285 proposed registration paths in GIST
BLU-285 proposed registration paths in GIST PDGFRα D842V-driven GIST Breakthrough Therapy Designation granted in June 2017 FDA open to considering additional Phase 1 data as basis for a New Drug Application Estimate expansion cohort enrollment complete by mid-year 2018 KIT-driven GIST Plan to initia
Slide 16: BLU-285 in advanced systemic mastocytosis
Advanced SM is a severe, rare disease and published natural history data show only ~3-5 years overall survival KIT D816V mutation is a key driver in ~90-95% of patients1 BLU-285 is a highly selective inhibitor of KIT D816V Proof-of-concept data for BLU-285 showed decreased bone marrow mast cell burd
Slide 17: Encouraging early clinical activity with objective decreases in mast cell burden
Encouraging early clinical activity with objective decreases in mast cell burden The values above/below the bars denote the dose level (mg) QD received by each patient. Data previously presented in December 2016 at the American Society of Hematology Annual Meeting. Data cutoff: November 11, 2016. 17
Slide 18: BLU-554 for Advanced Hepatocellular Carcinoma (HCC)
BLU-554 for Advanced Hepatocellular Carcinoma (HCC)
Slide 19: BLU-554 in advanced HCC
Sorafenib used first line with ~2% response rate; median time to progression 3-6 months Abnormally activated FGFR4 pathway in ~30% of patients enables biomarker-driven patient selection BLU-554 is a selective inhibitor of FGFR4 with encouraging early single agent activity in heavily pre-treated pati
Slide 20: Proof-of-concept established for BLU-554 in advanced HCC
Proof-of-concept established for BLU-554 in advanced HCC Phase 1 dose escalation summary: Achieved proof-of-concept in dose escalation portion of trial BLU-554 is preferentially active in biomarker positive patients MTD determined to be 600 mg QD 2 (8%) patients discontinued BLU-554 due to treatment
Slide 21: BLU-667 RET Inhibitor
BLU-667 RET Inhibitor (Sbwueprint,
Slide 22: BLU-667 is designed as a targeted inhibitor to achieve better RET inhibition
BLU-667 is designed as a targeted inhibitor to achieve better RET inhibition *Represents estimated prevalence for MTC patients with RET mutations and estimated incidence for NSCLC patients with RET fusions in major markets (US, EU5 and Japan). 23 1 2 3 ACTIVATING RET KINASE FUSIONS AND MUTATIONS ARE
Slide 23: Cash to fund operating expenses and capital expenditures into 2H 2019
Cash to fund operating expenses and capital expenditures into 2H 2019* *Cash guidance excludes any potential option fees and milestone payments under the existing collaboration with Roche. 24 SHARES OUTSTANDING as of 6/30/17 39.1 million (basic) 42.5 million (fully diluted) OUTSTANDING DEBT as of 6/
Slide 24: Potential 2H 2017 milestones
Potential 2H 2017 milestones 25 BLU-285 GIST Expand development plan to include opportunities for earlier lines of therapy or combinations BLU-285 SM Update data from Phase 1 study in advanced SM Expand clinical development plan to include indolent SM BLU-554 HCC Update data from Phase 1 study in ad
Slide 25: Thank you
Thank you
Blueprint Medicines — Investor Presentation (August 2017) on 6ix